34 results on '"Suzuki, Tadaki"'
Search Results
2. Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in a COVID-19 hamster model
- Author
-
Sasaki, Michihito, Sugi, Tatsuki, Iida, Shun, Hirata, Yuichiro, Kusakabe, Shinji, Konishi, Kei, Itakura, Yukari, Tabata, Koshiro, Kishimoto, Mai, Kobayashi, Hiroko, Ariizumi, Takuma, Intaruck, Kittiya, Nobori, Haruaki, Toba, Shinsuke, Sato, Akihiko, Matsuno, Keita, Yamagishi, Junya, Suzuki, Tadaki, Hall, William W., Orba, Yasuko, and Sawa, Hirofumi
- Published
- 2024
- Full Text
- View/download PDF
3. In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters
- Author
-
Furusawa, Yuri, Kiso, Maki, Iida, Shun, Uraki, Ryuta, Hirata, Yuichiro, Imai, Masaki, Suzuki, Tadaki, Yamayoshi, Seiya, and Kawaoka, Yoshihiro
- Published
- 2023
- Full Text
- View/download PDF
4. Evaluation of a novel severe combined immunodeficiency mouse model for antiviral drug evaluation against Chandipura virus infection
- Author
-
Kitaura, Satoshi, Tobiume, Minoru, Kawahara, Madoka, Satoh, Masaaki, Kato, Hirofumi, Nakayama, Noriko, Nakajima, Nozomi, Komeno, Takashi, Furuta, Yousuke, Suzuki, Tadaki, Moriya, Kyoji, Saijo, Masayuki, Ebihara, Hideki, and Takayama-Ito, Mutsuyo
- Published
- 2023
- Full Text
- View/download PDF
5. Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
- Author
-
Miyamoto, Sho and Suzuki, Tadaki
- Subjects
- *
SARS-CoV-2 , *BREAKTHROUGH infections , *SARS-CoV-2 Omicron variant , *IMMUNE response , *VIRAL antibodies , *SERUM , *COVID-19 vaccines - Abstract
• Breakthrough infections induce high Omicron-neutralizing antibodies. • Neutralizing antibody titers correlate with viral load and vaccination interval. • Omicron antigens trigger a distinct immune response from the vaccine strain. • Breakthrough infection provide insights into SARS-CoV-2 vaccine-induced immunity. • Next-generation vaccines can help control COVID-19 and prevent future pandemics. Post-vaccination infections, termed breakthrough infections, occur after the virus infection overcomes the vaccine-induced immune barrier. During the early stages of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron wave, high serum-neutralizing antibody titers against the Omicron variant were detected in individuals with breakthrough infections as well as those who received a third vaccine dose (i.e., booster recipients). Additionally, these cases indicated that Omicron antigens triggered an immune response that differed from that triggered by the vaccine strain before analysis of the effectiveness of new vaccines updated for the Omicron variants. Moreover, the magnitude and breadth of neutralizing antibody titers induced by breakthrough infections are correlated with the upper respiratory viral load at diagnosis and the duration between vaccination and infection, respectively. Unlike booster vaccine recipients, patients with breakthrough infections have varying durations between vaccination and infection. Accordingly, optimal booster vaccination intervals may be estimated based on the cross-neutralizing antibody response induced over time. Examination of breakthrough infection cases has provided valuable insights that could not be yielded by only examining vaccinated individuals alone. These insights include estimates of vaccine-induced immunity against SARS-CoV-2 variants and the various factors related to the clinical status. This review describes the immune response elicited by breakthrough infections; specifically, it discusses factors that affect the magnitude and breadth of serum antibody titers as well as the appropriate booster vaccination strategy. This review provides key aspects that could contribute to developing next-generation COVID-19 vaccines through breakthrough infection cases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Combatting infectious diseases; nanotechnology as a platform for rational vaccine design
- Author
-
van Riet, Elly, Ainai, Akira, Suzuki, Tadaki, Kersten, Gideon, and Hasegawa, Hideki
- Published
- 2014
- Full Text
- View/download PDF
7. Establishment of tracking system for West Nile virus entry and evidence of microtubule involvement in particle transport
- Author
-
Makino, Yoshinori, Suzuki, Tadaki, Hasebe, Rie, Kimura, Takashi, Maeda, Akihiko, Takahashi, Hidehiro, and Sawa, Hirofumi
- Published
- 2014
- Full Text
- View/download PDF
8. Restriction of SARS-CoV-2 replication in the human placenta.
- Author
-
Takada, Kazuhide, Shimodai-Yamada, Sayaka, Suzuki, Mayumi, Trinh, Quang Duy, Takano, Chika, Kawakami, Kaori, Asai-Sato, Mikiko, Komatsu, Atsushi, Okahashi, Aya, Nagano, Nobuhiko, Misawa, Toshiya, Yamaguchi, Kyohei, Suzuki, Tadaki, Kawana, Kei, Morioka, Ichiro, Yamada, Hideto, Hayakawa, Satoshi, Hao, Hiroyuki, and Komine-Aizawa, Shihoko
- Abstract
Although SARS-CoV-2 can infect human placental tissue, vertical transmission is rare. Therefore, the placenta may function as a barrier to inhibit viral transmission to the foetus, though the mechanisms remain unclear. In this study, we confirmed the presence of the SARS-CoV-2 genome in human placental tissue by in situ hybridization with antisense probes targeting the spike protein; tissue staining was much lower when using sense probes for the spike protein. To the best of our knowledge, this is the first evidence directly indicating inefficient viral replication in the SARS-CoV-2-infected placenta. Additional studies are required to reveal the detailed mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Progressive multifocal leukoencephalopathy in a patient with primary amyloid light-chain amyloidosis
- Author
-
Katsuse, Kazuto, Akiyama, Kaho, Ishida, Tadao, Kitayama, Chigusa, Ishibashi, Yoshitaka, Ochi, Mieko, Kumasaka, Toshio, Takahashi, Kenta, Suzuki, Tadaki, Nakamichi, Kazuo, Saijo, Masayuki, and Hashida, Hideji
- Published
- 2020
- Full Text
- View/download PDF
10. Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus.
- Author
-
Suzuki, Tadaki, Ainai, Akira, and Hasegawa, Hideki
- Subjects
- *
MUCOUS membranes , *IMMUNOGLOBULINS , *RESPIRATORY infections , *INFLUENZA A virus , *IMMUNIZATION - Abstract
Mucosal tissues are major targets for pathogens. The secretions covering mucosal surfaces contain several types of molecules that protect the host from infection. Among these, mucosal immunoglobulins, including secretory IgA (S-IgA) antibodies, are the major contributor to pathogen-specific immune responses. IgA is the primary antibody class found in many external secretions and has unique structural and functional features not observed in other antibody classes. Recently, extensive efforts have been made to develop novel vaccines that induce immunity via the mucosal route. S-IgA is a key molecule that underpins the mechanism of action of these mucosal vaccines. Thus, precise characterization of S-IgA induced by mucosal vaccines is important, if the latter are to be used successfully in a clinical setting. Intensive studies identified the fundamental characteristics of S-IgA, which was first discovered almost half a century ago. However, S-IgA itself has not gained much attention of late, despite its importance to mucosal immunity; therefore, some important questions remain. This review summarizes the current understanding of the molecular characteristics of S-IgA and its role in intranasal mucosal vaccines against influenza virus infection. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. Large T Antigen Promotes JC Virus Replication in G2-arrested Cells by Inducing ATM- and ATR-mediated G2 Checkpoint Signaling.
- Author
-
Orba, Yasuko, Suzuki, Tadaki, Makino, Yoshinori, Kubota, Kanako, Shinya Tanaka, Kimura, Takashi, and Sawa, Hirofumi
- Subjects
- *
ANTIGENS , *VIRAL replication , *SV40 (Virus) , *VIRAL genomes , *MICROBIAL cell cycle , *CAFFEINE , *PROGRESSIVE multifocal leukoencephalopathy , *TELOMERASE , *THERAPEUTICS - Abstract
Large T antigen (TAg) of the human polyomavirus JC virus (JCV) possesses DNA binding and helicase activities, which, together with various cellular proteins, are required for replication of the viral genome. We now show that JCV-infected cells expressing TAg accumulate in the G2 phase of the cell cycle as a result of the activation of ATMand ATR-mediated G2 checkpoint pathways. Transient transfectión of cells with a TAg expression vector also induced G2 checkpoint signaling and G2 arrest. Analysis of TAg mutants with different subnuclear localizations suggested that the association of TAg with cellular DNA contributes to the induction of G2 arrest. Abrogation of G2 arrest by inhibition of ATM and ATR, Chkl, and Wee! suppressed JCV genome replication. In addition, abrogation of the G2-M transition by Cdc2 depletion disabled Wee! depletioninduced suppression of JCV genome replication, suggesting that JCV replication is facilitated by G2 arrest resulting from G2 checkpoint signaling. Moreover, inhibition of ATM and ATR by caffeine suppressed JCV production. The observation that ohgodendrocytes productively infected with JCV in vivo also undergo G2 arrest suggests that G2 checkpoint inhibitors such as caffeine are potential therapeutic agents for JCV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
12. Identification of FEZ1 as a Protein That Interacts with JC Virus Agnoprotein and Microtubules.
- Author
-
Suzuki, Tadaki, Okada, Yuki, Semba, Shingo, Orba, Yasuko, Yamanouchi, Satoko, Endo, Shuichi, Tanaka, Shinya, Fujita, Toshitsugu, Kuroda, Shun'ichi, Nagashima, Kazuo, and Sawa, Hirofumi
- Subjects
- *
POLYOMAVIRUSES , *MICROTUBULES , *TUBULINS , *BRAIN , *CELLS - Abstract
The human polyomavirus JC virus (JCV) is the causative agent of a fatal demyelinating disease, progressive multifocal leukoencephalopathy, and encodes six major proteins, including agnoprotein. Agnoprotein colocalizes with microtubules in JCV-infected cells, but its function is not fully understood. We have now identified fasciculation and elongation protein zeta 1 (FEZ1) as a protein that interacted with JCV agnoprotein in a yeast two-hybrid screen of a human brain cDNA library. An in vitro binding assay showed that agnoprotein interacted directly with FEZ1 and microtubules. A microtubule cosedimentation assay revealed that FEZ1 also associates with microtubules and that agnoprotein induces the dissociation of FEZ1 from microtubules. Agnoprotein inhibited the promotion by FEZ1 of neurite outgrowth in PC12 cells. Conversely, overexpression of FEZ1 suppressed JCV protein expression and intracellular trafficking in JCV-infected cells. These results suggest that FEZ1 promotes neurite extension through its interaction with microtubules, and that agnoprotein facilitates JCV propagation by inducing the dissociation of FEZ1 from microtubules. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
13. Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection.
- Author
-
Ito, Wataru, Fukumori, Tatsuya, Asaoka, Nao, Imakita, Natsuko, Nishimura, Tomoko, Furukawa, Ryutaro, Nishihara, Yuji, Fujikura, Hiroyuki, Sekine, Takahiro, Yamaguchi, Naoki, Hirata, Yuichiro, Miyamoto, Sho, Kanno, Takayuki, Katano, Harutaka, Suzuki, Tadaki, and Kasahara, Kei
- Subjects
- *
COVID-19 , *CHOLECYSTITIS , *ACALCULOUS cholecystitis , *SARS-CoV-2 , *GAMMA-glutamyltransferase - Abstract
Immunocompromised patients with hematologic malignancies, particularly those treated with anti-CD20 antibodies such as rituximab and obinutuzumab, are known to be at risk of prolonged infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Prolonged administration or combination therapy with antiviral medications reportedly yields favorable outcomes in these patients. However, knowledge regarding the adverse events associated with such therapeutic approaches is limited. Herein, we report a case of acute acalculous cholecystitis (AAC) following extended administration of nirmatrelvir/ritonavir (NMV/r) in a 68-year-old Japanese man with persistent SARS-CoV-2 infection. The patient had received obinutuzumab and bendamustine for follicular lymphoma and was diagnosed with coronavirus disease 2019 (COVID-19) approximately one year after treatment initiation with these drugs. Subsequently, he was admitted to a different hospital, where he received antiviral drugs, monoclonal antibodies, and steroids. Despite these interventions, the patient relapsed and was subsequently transferred to our hospital due to persistent SARS-CoV-2 infection. Remdesivir administration was ineffective, leading to the initiation of extended NMV/r therapy. One week later, he exhibited elevated gamma-glutamyl transpeptidase (GGT) levels, and one month later, he developed AAC. Cholecystitis was successfully resolved via percutaneous transhepatic gallbladder drainage and administration of antibiotics. We speculate that extended NMV/r administration, in addition to COVID-19, may have contributed to the elevated GGT and AAC. During treatment of persistent SARS-CoV-2 infection with extended NMV/r therapy, patients should be carefully monitored for the appearance of findings suggestive of biliary stasis and the development of AAC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. A nationwide cross-sectional study using a web-based questionnaire survey of the duration of isolation of COVID-19 inpatients with cancer at Japanese cancer centers.
- Author
-
Itoh, Naoya, Akazawa, Nana, Kurai, Hanako, Kawamura, Ichiro, Okinaka, Keiji, Fujita, Takahiro, Sekiya, Noritaka, Takeda, Koichi, Shiotsuka, Mika, Ishikane, Masahiro, Iwamoto, Noriko, Ohmagari, Norio, and Suzuki, Tadaki
- Subjects
- *
COVID-19 , *INTERNET surveys , *CROSS-sectional method , *POLYMERASE chain reaction , *ANTIGEN analysis - Abstract
There is no clear consensus regarding the optimal isolation duration for immunocompromised patients with coronavirus disease 2019 (COVID-19). Therefore, we conducted a questionnaire survey at eight Japanese cancer centers to investigate the practices of infectious disease specialists regarding the duration of isolation for COVID-19 inpatients with cancer. For asymptomatic to severely ill COVID-19 inpatients without severe immunodeficiency, four centers reported at least 10 days of isolation without testing, and two reported at least 20 days. Two centers incorporated polymerase chain reaction (PCR) as a criterion for terminating the isolation of inpatients without severe immunodeficiency. For severely immunocompromised COVID-19 inpatients, at least 20 days of isolation were required in seven facilities, regardless of illness severity. Additionally, seven centers had implemented Ct or antigen quantification test values as criteria for de-isolating severely immunocompromised inpatients. No cases caused nosocomial outbreaks after isolation was terminated based on each facility's criteria for isolation termination. Thus, cancer patients required longer isolation periods than the general population in most facilities, and for those with severe immunodeficiency, the isolation periods were longer and more tightly controlled with tests. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
- Author
-
Chiba, Shiho, Halfmann, Peter J., Iida, Shun, Hirata, Yuichiro, Sato, Yuko, Kuroda, Makoto, Armbrust, Tammy, Spyra, Samuel, Suzuki, Tadaki, and Kawaoka, Yoshihiro
- Subjects
- *
IMMUNOGLOBULINS , *SARS-CoV-2 , *RECOMBINANT proteins , *GOLDEN hamster - Abstract
The spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a glycoprotein, expressed on the virion surface, that mediates infection of host cells by directly interacting with host receptors. As such, it is a reasonable target to neutralize the infectivity of the virus. Here we found that a recombinant S protein vaccine adjuvanted with Alhydrogel or the QS-21-like adjuvant Quil-A effectively induced anti-S receptor binding domain (RBD) serum IgG and neutralizing antibody titers in the Syrian hamster model, resulting in significantly low SARS-CoV-2 replication in respiratory organs and reduced body weight loss upon virus challenge. Severe lung inflammation upon virus challenge was also strongly suppressed by vaccination. We also found that the S protein vaccine adjuvanted with Alhydrogel, Quil-A, or an AS03-like adjuvant elicited significantly higher neutralizing antibody titers in mice than did unadjuvanted vaccine. Although the neutralizing antibody titers against the variant viruses B.1.351 and B.1.617.2 declined markedly in mice immunized with wild-type S protein, the binding antibody levels against the variant S proteins were equivalent to those against wild-type S. When splenocytes from the immunized mice were re-stimulated with the S protein in vitro, the induced Th1 or Th2 cytokine levels were not significantly different upon re-stimulation with wild-type S or variant S, suggesting that the T-cell responses against the variants were the same as those against the wild-type virus. Upon Omicron XBB-challenge in hamsters, wild-type S-vaccination with Alhydrogel or AS03 reduced lung virus titers on Day 3, and the Quil-A adjuvanted group showed less body weight loss, although serum neutralizing antibody titers against XBB were barely detected in vitro. Collectively, recombinant vaccines coupled with different adjuvants may be promising modalities to combat new variant viruses by inducing various arms of the immune response. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. A bivalent outer membrane vesicle-based intranasal vaccine to prevent infection of periodontopathic bacteria.
- Author
-
Nakao, Ryoma, Hirayama, Satoru, Yamaguchi, Takehiro, Senpuku, Hidenobu, Hasegawa, Hideki, Suzuki, Tadaki, Akeda, Yukihiro, and Ohnishi, Makoto
- Subjects
- *
EXTRACELLULAR vesicles , *ACTINOBACILLUS actinomycetemcomitans , *PORPHYROMONAS gingivalis , *VACCINE effectiveness , *INTRANASAL administration , *PERIODONTAL disease , *MOUTH , *SALIVARY glands - Abstract
Periodontal disease has become a serious public health problem, not only causing tooth loss, but also inducing chronic disorders of extra-oral organs. The present study assessed an intranasal vaccine strategy to prevent periodontal disease using outer membrane vesicles (OMVs) of two major periodontopathic bacteria, Porphyromonas gingivalis (Pg) and Aggregatibacter actinomycetemcomitans (Aa). We compared the morphology, composition, and immune activity between OMVs of Pg strain ATCC 33277 and Aa strain Y4. Aa OMVs had a smoother surface and stronger lipid A activity compared to Pg OMVs. The in vitro immune activity elicited by Aa OMVs in macrophage-like cells was remarkably stronger than that of Pg OMVs. Intranasal immunization of mice with Aa OMVs alone resulted in robust, humoral immune responses in blood and saliva. Despites the intrinsically low mucosal immunogenicity of Pg OMVs alone, using Aa OMVs as a mucosal adjuvant strongly enhanced Pg-specific immune responses, resulting in both serum IgG and salivary IgA, both of which aggregated Pg and Aa cells. Furthermore, Aa OMVs were found to be a more potent mucosal adjuvant than Poly(I:C) in the context of enhancing the production of Pg-specific IgG (especially IgG2a) and IgA. In addition, in a randomized, blinded study, mice oral challenged with Pg and Aa after intranasal immunization with Pg OMVs and Aa OMVs had significantly decreased numbers of both microorganisms compared to mock-immunized mice. Furthermore, in an intracerebral injection mouse model, there were no serious adverse effects on the brain even after administrating a dose of OMVs as same as that used for intranasal administration. Taken together, the bivalent OMV intranasal vaccine may be effective in preventing colonization of periodontopathic bacteria in the oral cavity and related systemic disorders associated with periodontal diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. The road to a more effective influenza vaccine: Up to date studies and future prospects.
- Author
-
Sano, Kaori, Ainai, Akira, Suzuki, Tadaki, and Hasegawa, Hideki
- Subjects
- *
INFLUENZA vaccines , *VACCINE effectiveness , *RESPIRATORY disease prevention , *POINT mutation (Biology) , *VIRAL genomes - Abstract
Influenza virus causes an acute respiratory infection in humans. Frequent point mutations in the influenza genome and occasional exchange of genetic segments between virus strains help the virus evade the pre-existing immunity, resulting in epidemics and pandemics. Although vaccination is the most effective intervention, mismatches between circulating viruses and vaccine strains reduce vaccine efficacy. Furthermore, current injectable vaccines induce IgG antibodies in serum (which limit progression of influenza symptoms) but not secretory IgA antibodies in the respiratory mucosa (which prevent virus infection efficiently). Therefore, numerous studies have attempted to improve influenza vaccines. The discovery of broadly neutralizing antibodies has progressed research into antigen design. Studies designed to improve vaccine efficacy by changing the vaccine administration route have also been conducted. A thorough understanding of the mechanisms underlying the action of various vaccines is essential if we are to develop a universal influenza vaccine. Therefore, evaluating the quality and quantity of antibodies induced by vaccines, which determine vaccine efficacy, is critical. However, at present vaccine evaluation relies on hemagglutination inhibition tests, which only measure the quantity of antibody produced. Antibody repertoires comprise a set of antibodies with specific genetic or molecular features that correspond to their functions. Genetically and functionally similar antibodies may be produced by multiple individuals exposed to an identical stimulus. Therefore, it may be possible to evaluate and compare multiple vaccine strategies in terms of the quality and quantity of an antibody response induced by a vaccine by examining antibody repertoires. Recent studies have used single cell expression and high-throughput immunoglobulin sequencing to provide a detailed picture of antibody responses. These novel methods may be critical for detailed characterization of antibody repertoires induced by various vaccination strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
18. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
- Author
-
Sonoyama, Takuhiro, Iwata, Satoshi, Shinkai, Masaharu, Iwata-Yoshikawa, Naoko, Shiwa-Sudo, Nozomi, Hemmi, Takuya, Ainai, Akira, Nagata, Noriyo, Matsunaga, Nobuaki, Tada, Yukio, Homma, Tomoyuki, Omoto, Shinya, Yokokawa Shibata, Risa, Igarashi, Kenji, Suzuki, Tadaki, Hasegawa, Hideki, and Ariyasu, Mari
- Subjects
- *
MICE , *SARS-CoV-2 , *JAPANESE people , *COVID-19 vaccines - Abstract
• S-268019-a is a recombinant spike protein vaccine adjuvanted with agatolimod sodium. • S-268019-a elicited immunogenicity and efficacy against SARS-CoV-2 in mice. • S-268019-a was safe but insufficiently immunogenic in humans. • Translating preclinical data to clinical studies is innately challenging. • S-268019-b formulation with a squalene-based adjuvant is in Phase 3 clinical trials. In early 2020, developing vaccines was an urgent need for preventing COVID-19 from a contingency perspective. S-268019-a is a recombinant protein-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising a modified recombinant spike protein antigen adjuvanted with agatolimod sodium, a Toll-like receptor-9 agonist. In the preclinical phase, it was administered intramuscularly twice at a 2-week interval in 7-week-old mice. Immunogenicity was assessed, and the mice were challenged intranasally with mouse-adapted SARS-CoV-2 at 2 and 8 weeks, respectively, after the second immunization. After confirming the preclinical effect, a Phase 1/2, randomized, parallel-group clinical study was conducted in healthy adults (aged 20–64 years). All participants received 2 intramuscular injections at various combinations of the antigen and the adjuvant (S-910823/agatolimod sodium, in μg: 12.5/250, 25/250, 50/250, 25/500, 50/500, 100/500, 10/500, 100/100, 200/1000) or placebo (saline) in an equivalent volume at a 3-week interval and were followed up until Day 50 in this interim analysis. In the preclinical studies, S-268019-a was safe and elicited robust immunoglobulin G (IgG) and neutralizing antibody responses in mice. When challenged with SARS-CoV-2, all S-268019-a-treated mice survived and maintained weight until 10 days, whereas all placebo- or adjuvant-treated (without antigen) mice died within 6 days. In the Phase 1/2 trial, although S-268019-a was well tolerated in adult participants, was safe up to Day 50, and elicited robust anti-spike protein IgG antibodies, it did not elicit sufficient neutralizing antibody levels. The S-268019-a vaccine was not sufficiently immunogenic in Japanese adults despite robust immunogenicity and efficacy in mice. Our results exemplify the innate challenges in translating preclinical data in animals to clinical trials, and highlight the need for continued research to overcome such barriers. (jRCT2051200092) [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Successful treatment of proven coronavirus disease 2019-associated pulmonary aspergillosis with liposomal amphotericin B in a patient with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
- Author
-
Nakaya, Yosuke, Nakashima, Yasuhiro, Harada, Naonori, Yamada, Koichi, Makuuchi, Yosuke, Kuno, Masatomo, Takakuwa, Teruhito, Okamura, Hiroshi, Nanno, Satoru, Nishimoto, Mitsutaka, Koh, Hideo, Nakagama, Yu, Kido, Yasutoshi, Kanno, Takayuki, Suzuki, Tadaki, Nakamae, Hirohisa, Kakeya, Hiroshi, and Hino, Masayuki
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *CORONAVIRUS disease treatment , *PULMONARY aspergillosis , *AMPHOTERICIN B , *COVID-19 , *LUNG diseases , *BRONCHIOLITIS obliterans syndrome - Abstract
Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is being increasingly recognized as a severe complication that contributes to poor prognoses among patients with COVID-19. However, little is known regarding the clinical course of CAPA with hematological malignancies, especially after allogeneic hematopoietic stem cell transplantation (HSCT). A 29-year-old woman was diagnosed with proven CAPA with an Aspergillus fumigatus identified by cultures of bronchoalveolar lavage and lung biopsy four years after haploidentical HSCT for acute myelogenous leukemia. She had been taking oral prednisolone for bronchiolitis obliterans syndrome that developed after HSCT. Although prolonged RT-PCR positivity for SARS-CoV-2 (133 days after the onset of COVID-19) without shedding of viable virus was observed, the COVID-19 was treated with favipiravir, remdesivir, dexamethasone, and enoxaparin. However, the CAPA did not respond to combination therapy, which included triazole (voriconazole, itraconazole, posaconazole) and echinocandin (caspofungin, micafungin), even though the Aspergillus fumigatus isolate was found to be susceptible to these agents in vitro. Nevertheless, a total of 16 weeks of liposomal amphotericin B (L-AMB) therapy led to a favorable response, and the patient was discharged from the hospital on day 213. This case provided essential experience of CAPA treated with L-AMB in a recipient with chronic respiratory disease after HSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine.
- Author
-
Saito, Shinji, Ainai, Akira, Suzuki, Tadaki, Harada, Norihiro, Ami, Yasushi, Yuki, Yoshikazu, Takeyama, Haruko, Kiyono, Hiroshi, Tsukada, Hideo, and Hasegawa, Hideki
- Subjects
- *
ANTIBODY formation , *INFLUENZA vaccines , *INTRANASAL medication , *IMMUNE system , *LABORATORY mice - Abstract
Introduction Recently, we reported that intranasal vaccination of humans with whole inactivated influenza vaccine in the absence of mucosal adjuvant induced neutralizing antibody responses in the serum and nasal mucus. The mucoadhesive excipient carboxy-vinyl polymer (CVP) increases the viscosity and therefore mucoadhesiveness of intranasal medicaments and is an authorized excipient in Japan. In the present study, we analyzed the effect of adding CVP on intranasal whole inactivated influenza vaccine antigen dynamics and antibody responses. Methods Mice and nonhuman primates (NHPs) were intranasally administered the [ 18 F]-radiolabeled vaccine and subjected to positron emission tomography analysis for 6 h. Dendritic cells were stimulated in vitro with the vaccine mixed with or without a mucosal adjuvant (Ampligen) and/or CVP, after which the tumor necrosis factor (TNF)-α and interferon (IFN)-β levels in the supernatants were measured. Cynomolgus monkeys were immunized intranasally with the vaccine mixed with Ampligen and/or CVP and their vaccine-specific serum IgG and IgA titers were measured on days 0 and 33. Results The vaccine was retained significantly longer in the nasal cavity of both mice and NHPs when it was delivered with CVP rather than PBS. Accumulation of the radiolabeled vaccine in the central nervous system was not detected in either model regardless of whether CVP was used. CVP only very weakly increased the TNF-α production of vaccine-stimulated dendritic cells. IFN-β production was not observed regardless of the presence or absence of CVP. CVP increased the vaccine-specific IgA antibody responses of the intranasally vaccinated cynomolgus macaques. Conclusion CVP increased intranasal retention of whole inactivated influenza vaccine, did not promote antigen redirection to the central nervous system, and improved mucosal antibody responses. The mechanism probably relates to its mucoadhesive properties rather than its ability to directly stimulate the immune system. Intranasal vaccines with CVP may be a promising candidate vaccine formulation for humans. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
21. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
- Author
-
Hemmi, Takuya, Ainai, Akira, Hashiguchi, Takao, Tobiume, Minoru, Kanno, Takayuki, Iwata-Yoshikawa, Naoko, Iida, Shun, Sato, Yuko, Miyamoto, Sho, Ueno, Akira, Sano, Kaori, Saito, Shinji, Shiwa-Sudo, Nozomi, Nagata, Noriyo, Tamura, Koji, Suzuki, Ryosuke, Hasegawa, Hideki, and Suzuki, Tadaki
- Subjects
- *
LUNGS , *IMMUNOGLOBULINS , *COVID-19 , *SARS-CoV-2 , *IMMUNOGLOBULIN A - Abstract
To control the coronavirus disease 2019 (COVID-19) pandemic, there is a need to develop vaccines to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. One candidate is a nasal vaccine capable of inducing secretory IgA antibodies in the mucosa of the upper respiratory tract, the initial site of infection. However, regarding the development of COVID-19 vaccines, there is concern about the potential risk of inducing lung eosinophilic immunopathology as a vaccine-associated enhanced respiratory disease as a result of the T helper 2 (Th2)-dominant adaptive immune response. In this study, we investigated the protective effect against virus infection induced by intranasal vaccination of recombinant trimeric spike protein derived from SARS-CoV-2 adjuvanted with CpG oligonucleotides, ODN2006, in mouse model. The intranasal vaccine combined with ODN2006 successfully induced not only systemic spike-specific IgG antibodies, but also secretory IgA antibodies in the nasal mucosa. Secretory IgA antibodies showed high protective ability against SARS-CoV-2 variants (Alpha, Beta and Gamma variants) compared to IgG antibodies in the serum. The nasal vaccine of this formulation induced a high number of IFN-γ-secreting cells in the draining cervical lymph nodes and a lower spike-specific IgG1/IgG2a ratio compared to that of subcutaneous vaccination with alum as a typical Th2 adjuvant. These features are consistent with the induction of the Th1 adaptive immune response. In addition, mice intranasally vaccinated with ODN2006 showed less lung eosinophilic immunopathology after viral challenge than mice subcutaneously vaccinated with alum adjuvant. Our findings indicate that intranasal vaccine adjuvanted with ODN2006 could be a candidate that can prevent the infection of antigenically different variant viruses, reducing the risk of vaccine-associated enhanced respiratory disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy.
- Author
-
Kamegai, Kohei, Iwamoto, Noriko, Togano, Tomiteru, Maeda, Kenji, Takamatsu, Yuki, Miyazato, Yusuke, Ishikane, Masahiro, Mizokami, Masashi, Sugiyama, Masaya, Iida, Shun, Miyamoto, Sho, Suzuki, Tadaki, and Ohmagari, Norio
- Subjects
- *
RITUXIMAB , *SARS-CoV-2 Delta variant , *MUCOSA-associated lymphoid tissue lymphoma , *COVID-19 pandemic , *MESSENGER RNA , *SEZARY syndrome - Abstract
• We report a fatal case of breakthrough infection with the SARS-CoV-2 Delta variant after the first vaccination course. • Patients with hematologic malignancies are vulnerable to COVID-19 viral infection. • Surveillance of mixed alleles could help detect unknown aggravating factors. Although messenger ribonucleic acid vaccines are substantially effective toward SARS-CoV-2 infection, patients with hematologic malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 Delta variant infection in a patient with mucosa-associated lymphoid tissue lymphoma with remission by bendamustine-rituximab (BR) therapy completed a year ago. The serologic study revealed impaired responsiveness toward vaccines and prolonged high viral load after infection. BR therapy seemingly induced an immune escape. Prevention and treatment strategies for such vulnerable patients should be clarified immediately. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
- Author
-
Hashimoto, Masayuki, Nagata, Noriyo, Homma, Tomoyuki, Maeda, Hiroki, Dohi, Keiji, Seki, Naomi M., Yoshihara, Ken, Iwata-Yoshikawa, Naoko, Shiwa-Sudo, Nozomi, Sakai, Yusuke, Shirakura, Masayuki, Kishida, Noriko, Arita, Tomoko, Suzuki, Yasushi, Watanabe, Shinji, Asanuma, Hideki, Sonoyama, Takuhiro, Suzuki, Tadaki, Omoto, Shinya, and Hasegawa, Hideki
- Subjects
- *
IMMUNOGLOBULINS , *SARS-CoV-2 , *KRA , *SARS-CoV-2 Omicron variant , *VITRONECTIN , *IMMUNE response - Abstract
• A novel SARS-CoV-2 recombinant spike (S)-protein vaccine S-268019-b was developed. • S-268019-b induced antibodies against S-protein and its receptor binding domain. • Neutralizing antibody was induced against SARS-CoV-2 and pseudovirus variants. • S-268019-b demonstrated protective efficacy against SARS-CoV-2 challenge. • S-268019-b was safe for use in cynomolgus macaques. The vaccine S-268019-b is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-protein vaccine consisting of full-length recombinant SARS-CoV-2 S-protein (S-910823) as antigen, mixed with the squalene-based adjuvant A-910823. The current study evaluated the immunogenicity of S-268019-b using various doses of S-910823 and its vaccine efficacy against SARS-CoV-2 challenge in cynomolgus monkeys. The different doses of S-910823 combined with A-910823 were intramuscularly administered twice at a 3-week interval. Two weeks after the second dosing, dose-dependent humoral immune responses were observed with neutralizing antibody titers being comparable to that of human convalescent plasma. Pseudoviruses harboring S proteins from Beta and Gamma SARS-CoV-2 variants displayed approximately 3- to 4-fold reduced sensitivity to neutralizing antibodies induced after two vaccine doses compared with that against ancestral viruses, whereas neutralizing antibody titers were reduced >14-fold against the Omicron variant. Cellular immunity was also induced with a relative Th1 polarized response. No adverse clinical signs or weight loss associated with the vaccine were observed, suggesting safety of the vaccine in cynomolgus monkeys. Immunization with 10 µg of S-910823 with A-910823 demonstrated protective efficacy against SARS-CoV-2 challenge according to genomic and subgenomic viral RNA transcript levels in nasopharyngeal, throat, and rectal swab specimens. Pathological analysis revealed no detectable vaccine-dependent enhancement of disease in the lungs of challenged vaccinated monkeys. The current findings provide fundamental information regarding vaccine doses for human trials and support the development of S-268019-b as a safe and effective vaccine for controlling the current pandemic, as well as general protection against SARS-CoV-2 moving forward. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Prolonged SARS-CoV-2 infection associated with long-term corticosteroid use in a patient with impaired B-cell immunity.
- Author
-
Morishita, Momoko, Suzuki, Manabu, Matsunaga, Akihiro, Ishizhima, Keishi, Yamamoto, Tsukasa, Kuroda, Yudai, Kanno, Takayuki, Tsujimoto, Yoshie, Ishida, Akane, Hashimoto, Masao, Ishii, Satoru, Takasaki, Jin, Naka, Go, Iikura, Motoyasu, Izumi, Shinyu, Suzuki, Tadaki, Maeda, Ken, Ishizaka, Yukihito, Hojo, Masayuki, and Sugiyama, Haruhito
- Subjects
- *
SARS-CoV-2 , *CORTICOSTEROIDS , *CELLULAR immunity , *IMMUNITY , *NON-Hodgkin's lymphoma - Abstract
Corticosteroids are widely used to treat severe COVID-19, but in immunocompromised individuals, who are susceptible to persistent infection, long term corticosteroid use may delay viral clearance. We present a case of prolonged SARS-CoV-2 infection in a man with significantly impaired B-cell immunity due to non-Hodgkin lymphoma which had been treated with rituximab. SARS-CoV-2 shedding persisted, despite treatment with remdesivir. Viral sequencing confirmed the persistence of the same viral strain, ruling out the possibility of reinfection. Although SARS-CoV-2 IgG, IgA and IgM remained negative throughout the treatment period, after reduction of the corticosteroid dose, PCR became negative. Long-term corticosteroid treatment, especially in immunocompromised individuals, may result in suppression of cell-mediated immunity and prolonged SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design
- Author
-
van Riet, Elly, Ainai, Akira, Suzuki, Tadaki, and Hasegawa, Hideki
- Subjects
- *
IMMUNOGLOBULIN A , *INFLUENZA viruses , *VIRUS diseases , *POINT mutation (Biology) , *CELL surface antigens , *CD4 antigen , *T cells , *B cells , *HUMORAL immunity - Abstract
Abstract: The current challenge in influenza vaccine design is to induce long-lasting protection not only against the vaccine strain, but also against drifted (point mutations in the surface antigens HA or NA) and even shifted (exchange of genome segments) strains. Several immune mediators that can induce cross-protection have been described, such as CD4 T-cells, CD8 T-cells and antibodies, including IgA. However, most vaccines are now administered intramuscularly or subcutaneously and subsequently relatively little is known on the role of local, mucosal responses. Since local IgA responses have been shown to play an important role in responses to natural infection, and IgA responses in mice were shown to also be involved in cross-protection, the research on mucosal influenza vaccines is currently expanding. However, the functioning of the mucosal immune system, especially in the respiratory tract, is just beginning to be revealed. Here, the current knowledge on the induction of IgA, the role of influenza specific IgA producing B-cells in anti-influenza immunity as well as the role of humoral memory responses induced upon vaccination will be reviewed. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
26. Nuclear Entry Mechanism of the Human Polyomavirus JC Virus-like Particle.
- Author
-
Qiumin Qu, Sawa, Hirofumi, Suzuki, Tadaki, Semba, Shingo, Henmi, Chizuka, Okada, Yuki, Tsuda, Masumi, Tanaka, Shinya, Atwood, Walter J., and Nagashima, Kazuo
- Subjects
- *
VIRUS diseases , *DNA viruses , *MIRIDAE , *FLUORESCEIN , *AGGLUTININS , *PROTEOLYSIS - Abstract
JC virus (JCV) belongs to the polyomavirus family of double-stranded DNA viruses and causes progressive multifocal leukoencephalopathy in humans. Although transport of virions to the nucleus is an important step in JCV infection, the mechanism of this process has remained unclear. The outer shell of the JCV virion comprises the major capsid protein VP1, which possesses a putative nuclear localization signal (NLS), and virus-like particles (VLPs) consisting of recombinant VP1 exhibit a virion-like structure and physiological functions (cellular attachment and intracytoplasmic trafficking) similar to those of JCV virions. We have now investigated the mechanism of nuclear transport of JCV with the use of VLPs. Wild-type VLPs (wtVLPs) entered the nucleus of most HeLa or SVG cells. The virion structure of VLPs was preserved during transport to the nucleus as revealed by confocal microscopy of cells inoculated with fluorescein isothiocyanate-labeled wtVLPs containing packaged Cy3. The nuclear transport of wtV- LPs in digitonin-permeabilized cells was dependent on the addition of importins α and β and was prevented by wheat germ agglutinin or by antibodies to the nuclear pore complex. The nuclear entry of VLPs composed of VP1 with a mutated NLS was greatly inhibited, compared with that of wtVLPs, in both intact and permeabilized cells. Unlike wtVLPs, the mutant VLPs did not bind to importins α or β. Limited proteolysis analysis revealed that the NLS of VP1 was exposed on the surface of wtVLPs. These results suggest that JCV VLPs bind to cellular importins via the NLS of VP1 and are transported into the nucleus through the nuclear pore complex. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
27. SARS-CoV-2 is localized in cardiomyocytes: a postmortem biopsy case.
- Author
-
Nakamura, Yoshihiko, Katano, Harutaka, Nakajima, Noriko, Sato, Yuko, Suzuki, Tadaki, Sekizuka, Tsuyoshi, Kuroda, Makoto, Izutani, Yoshito, Morimoto, Shinichi, Maruyama, Junichi, Koie, Megumi, Kitamura, Taisuke, and Ishikura, Hiroyasu
- Subjects
- *
TAKOTSUBO cardiomyopathy , *SARS-CoV-2 , *LEFT ventricular dysfunction , *ADULT respiratory distress syndrome , *MULTIPLE organ failure , *COVID-19 - Abstract
• Pathogenesis of acute cardiac injury with COVID-19 remains unknown • The patient experienced shock due to takotsubo cardiomyopathy with COVID-19 • SARS-CoV-2 antigen was detected in cardiomyocytes by immunostaining • SARS-CoV-2 detection in cardiomyocytes suggests an association with cardiac injury A 72-year-old patient was admitted to the intensive care unit due to acute respiratory distress syndrome caused by COVID-19. On day 20, the patient experienced shock. The electrocardiogram showed ST segment elevation in leads V3–V6 and severe left ventricular dysfunction with an ejection fraction of 35%–40%. The left ventricle showed basal hypokinesis and apical akinesis, while the creatine kinase level was normal, indicating Takotsubo cardiomyopathy. On day 24, the patient died of multiple organ failure. In post-mortem biopsy, SARS-CoV-2 antigen was detected in cardiomyocytes by immunostaining. Moreover, SARS-CoV-2 RNA was detected in heart tissue. We need to further analyse the direct link between SARS-CoV-2 and cardiomyocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity.
- Author
-
Moriyama, Yuki, Ishikane, Masahiro, Ueno, Mikako, Matsunaga, Akihiro, Ishizaka, Yukihito, Arashiro, Takeshi, Kanno, Takayuki, Suzuki, Tadaki, and Kimura, Kenjiro
- Subjects
- *
SARS-CoV-2 Delta variant , *SARS-CoV-2 , *BREAKTHROUGH infections , *CORONAVIRUS diseases , *MEDICAL personnel , *IMMUNOGLOBULIN G , *RUBELLA - Abstract
There have been several reports of breakthrough infections, which are defined as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among individuals who had received at least two doses of vaccine at least 14 days before the onset of infection, but data on the antibody titers, including SARS-CoV-2 neutralizing antibody activity, and the clinical course of individuals with breakthrough infections are limited. We encountered a case of breakthrough infection with the SARS-CoV-2 delta variant in a 31-year-old female healthcare worker (the index case, Case 1) and a secondary case (Case 2) in her unvaccinated 33-year-old husband. We studied the role of the anti-spike immunoglobulin G (IgG) and neutralizing antibody activity in the two case patients. Case 1 had high anti-spike IgG detected on day 3 of the illness, with low neutralizing antibody activity. The neutralizing antibody activity started to increase on day 5 of the illness. In Case 2 both the anti-spike IgG and the neutralizing antibody activity remained low from days 4–11 of illness, and the anti-spike IgG gradually increased from day 9. In Case 1, the fever broke within 4 days of onset, coinciding with the rise in neutralizing antibodies, whereas the fever took 7 days to resolve in Case 2. SARS-CoV-2 infection can occur even in vaccinated individuals, but vaccination may contribute to milder clinical symptoms because neutralizing antibodies are induced earlier in vaccinated individuals than in unvaccinated individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Effectiveness of personal protective equipment in preventing severe acute respiratory syndrome coronavirus 2 infection among healthcare workers.
- Author
-
Suzuki, Tetsuya, Hayakawa, Kayoko, Ainai, Akira, Iwata-Yoshikawa, Naoko, Sano, Kaori, Nagata, Noriyo, Suzuki, Tadaki, Wakimoto, Yuji, Akiyama, Yutaro, Miyazato, Yusuke, Nakamura, Keiji, Ide, Satoshi, Nomoto, Hidetoshi, Nakamoto, Takato, Ota, Masayuki, Moriyama, Yuki, Sugiki, Yuko, Saito, Sho, Morioka, Shinichiro, and Ishikane, Masahiro
- Subjects
- *
COVID-19 , *PERSONAL protective equipment , *ENZYME-linked immunosorbent assay , *SARS-CoV-2 - Abstract
Information on the effectiveness of personal protective equipment (PPE) for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among healthcare workers (HCWs), especially among HCWs with frequent contact with patients with SARS-CoV-2, is limited. We conducted a prospective cohort study on 49 HCWs who worked in close contact with patients with SARS-CoV-2 infection. HCWs had blood samples taken every 2 weeks to test for SARS-CoV-2 antibodies using two different types of assay. Forty-nine participants (31 nurses, 15 doctors, 3 other workers) were enrolled. In total, 112 blood samples are obtained from participants. The median work days in 2 weeks was 9 (interquartile range (IQR): 5–10) days. In a single work day, 30 of the 49 participants (61.5%) had contact with patients with suspected or conformed SARS-CoV-2 at least 8 times, and approximately 60% of participants had more than 10 min of contact with a single patient. The median self-reported compliance to PPE was 90% (IQR: 80–100%). Seven participants tested positive for SARS-CoV-2 antibody using enzyme-linked immunosorbent assay (ELISA); however, none were seropositive for SARS-CoV-2 neutralizing antibody, so the positive ELISA results were assumed to be false-positive. The study provides evidence that appropriate PPE is sufficient to prevent infection amongHCWs. It is necessary to establish a system that provides a stable supply of PPE for HCWs to perform their duties. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. A patient with severe fever with thrombocytopenia syndrome and hemophagocytic lymphohistiocytosis-associated involvement of the central nervous system.
- Author
-
Kaneko, Masahiko, Shikata, Hisaharu, Matsukage, Shoichi, Maruta, Masaki, Shinomiya, Hiroto, Suzuki, Tadaki, Hasegawa, Hideki, Shimojima, Masayuki, and Saijo, Masayuki
- Subjects
- *
THROMBOCYTOPENIA , *LYMPHADENITIS , *IMMUNOHISTOCHEMISTRY , *PATHOLOGICAL physiology , *OLDER patients , *DIAGNOSIS - Abstract
Severe fever with thrombocytopenia syndrome (SFTS), a severe infectious disease caused by novel bunyavirus, SFTS virus (SFTSV), is endemic to China, Korea, and Japan. Most SFTS patients show abnormalities in consciousness. Pathological findings in the central nervous system (CNS) of SFTS patients are not reported. A 53-year-old Japanese man was admitted to Uwajima City Hospital with an 8-day history of fever and diarrhea. Laboratory tests revealed leukopenia, thrombocytopenia, and liver enzyme elevation. He was diagnosed as having severe fever with thrombocytopenia syndrome (SFTS) following detection of the SFTSV genome in his blood. Bone marrow aspiration revealed hemophagocytic lymphohistiocytosis. He suffered progressive CNS disturbance and died on day 13 from onset of first symptoms. The SFTSV genome load in blood and levels of certain cytokines increased over the disease course. Necrotizing lymphadenitis with systemic lymphoid tissues positive for nucleocapsid protein (NP) of SFTSV was revealed by immunohistochemical (IHC) analysis. SFTSV-NP-positive immunoblasts were detected in all organs examined, including the CNS, and in the vascular lumina of each organ. Parenchymal cells of all organs examined were negative for SFTSV-NP on IHC analysis. Microscopic examination of the pons showed focal neuronal cell degeneration with hemosiderin-laden macrophages around extended microvessels with perivascular inflammatory cell infiltration and intravascular fibrin deposition. Autopsy confirmed this patient with SFTS was positive for systemic hemophagocytic lymphohistiocytosis including in the CNS. This patient's neurological abnormalities may have been caused by both functional and organic abnormalities. These novel findings provide important insights into the pathophysiology of SFTS. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
31. Application of HTLV-1 tax transgenic mice for therapeutic intervention.
- Author
-
Hasegawa, Hideki, Sano, Kaori, Ainai, Akira, and Suzuki, Tadaki
- Subjects
- *
TREATMENT of HTLV diseases , *HTLV disease immunology , *CANCER chemotherapy , *DRUG resistance , *LABORATORY mice ,DISEASES in adults - Abstract
Adult T-cell leukemia-lymphoma (ATL) is a refractory T-cell malignancy caused by infection of human T-cell leukemia virus type I (HTLV-I). Although the pathogenesis of ATL remains unclear, HTLV-1 oncoprotein Tax plays an important role in pathogenesis (Matsuoka, 2003; Jeang et al., 2004). Chemotherapy resistance of ATL leads the poor prognosis of this disease. In order to understand the pathogenesis and establish an animal model useful for therapy attempts, we have generated HTLV-1 Tax transgenic mice using the Lck proximal promoter to restrict the Tax expression in T-cells. The HTLV-1 Tax transgenic mice developed diffuse large-cell lymphomas and leukemia with the similar features of a clinical, pathological and immunological characteristic of acute ATL. The fulminant disease also developed rapidly in SCID mice after engraftment of mouse ATL cells derived from the transgenic mice. In this review, we introduce the therapeutic attempts using this animal model and discuss the possible signaling pathway for a therapeutic target. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
32. Microthrombosis as a cause of fulminant myocarditis-like presentation with COVID-19 proven by endomyocardial biopsy.
- Author
-
Nakatani, Satoshi, Ohta-Ogo, Keiko, Nishio, Mayu, Amemiya, Kisaki, Sato, Shuho, Sawano, Hirotaka, Hatakeyama, Kinta, Katano, Harutaka, Suzuki, Tadaki, and Hirooka, Keiji
- Subjects
- *
MYOCARDIAL injury , *COVID-19 , *BIOPSY , *INJURY complications , *MYOCARDITIS - Abstract
• Mechanisms of myocardial injury as a complication of COVID-19 have not been well understood. • We experienced a case with cardiogenic shock infected by COVID-19. • With endomyocardial biopsy, there was no sign of typical active myocarditis. • Ischemic changes were found at microvascular level accompanied by microthrombi. • Microvascular thrombotic injury is shown as a cause of fulminant myocarditis-like presentation. Myocardial injury has been reported as a complication of COVID-19. Although several mechanisms have been proposed as its cause, they are mostly based on autopsy studies, We report a 49-year-old male with COVID-19-associated myocardial injury presented like fulminant myocarditis. We performed endomyocardial biopsy on day 2 and we confirmed the presence of microthrombosis histologically. He died on day 5 due to cardiogenic shock. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
- Author
-
Ohashi, Hirofumi, Hishiki, Takayuki, Akazawa, Daisuke, Kim, Kwang Su, Woo, Joohyeon, Shionoya, Kaho, Tsuchimoto, Kana, Iwanami, Shoya, Moriyama, Saya, Kinoshita, Hitomi, Yamada, Souichi, Kuroda, Yudai, Yamamoto, Tsukasa, Kishida, Noriko, Watanabe, Shinji, Hasegawa, Hideki, Ebihara, Hideki, Suzuki, Tadaki, Maeda, Ken, and Fukushi, Shuetsu
- Subjects
- *
SARS-CoV-2 , *VIRAL antibodies , *SARS-CoV-2 Omicron variant , *ANTIVIRAL agents , *CELL culture - Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2 has spread in many countries, replacing the earlier Omicron subvariant BA.1 and other variants. Here, using a cell culture infection assay, we quantified the intrinsic sensitivity of BA.2 and BA.1 compared with other variants of concern, Alpha, Gamma, and Delta, to five approved-neutralizing antibodies and antiviral drugs. Our assay revealed the diverse sensitivities of these variants to antibodies, including the loss of response of both BA.1 and BA.2 to casirivimab and of BA.1 to imdevimab. In contrast, EIDD-1931 and nirmatrelvir showed a more conserved activities to these variants. The viral response profile combined with mathematical analysis estimated differences in antiviral effects among variants in the clinical concentrations. These analyses provide essential evidence that gives insight into variant emergence's impact on choosing optimal drug treatment. • Antiviral potency of casirivimab, imdevimab, and S309 were impaired to BA.1 and BA.2. • The inhibition profile of the tested antibodies was diverse between BA.1 and BA.2. • EIDD-1931 and nirmatrelvir showed more conserved antiviral activities among variants. • Antiviral effects at clinical drug concentrations were estimated. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
- Author
-
Ueno, Mikako, Iwata-Yoshikawa, Naoko, Matsunaga, Akihiro, Okamura, Tadashi, Saito, Sho, Ashida, Shinobu, Yoshida, Isao, Nagashima, Mami, Asakura, Hiroyuki, Yaoita, Yuu, Suzuki, Jun, Sadamasu, Kenji, Yoshimura, Kazuhisa, Kutsuna, Satoshi, Shiwa-Sudo, Nozomi, Nagata, Noriyo, Suzuki, Tadaki, Suzuki, Akinori, Okamoto, Miwa, and Kimura, Moto
- Subjects
- *
MONOCLONAL antibodies , *SARS-CoV-2 Omicron variant , *SARS-CoV-2 , *SARS-CoV-2 Delta variant , *MONONUCLEAR leukocytes - Abstract
Monoclonal antibody therapy is a promising option for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a cocktail of antibodies (REGN-COV) has been administered to infected patients with a favorable outcome. However, it is necessary to continue generating novel sets of monoclonal antibodies with neutralizing activity because viral variants can emerge that show resistance to the currently utilized antibodies. Here, we isolated a new cocktail of antibodies, EV053273 and EV053286, from peripheral blood mononuclear cells derived from convalescent patients infected with wild-type SARS-CoV-2. EV053273 exerted potent antiviral activity against the Wuhan wild-type virus as well as the Alpha and Delta variants in vitro , whereas the antiviral activity of EV053286 was moderate, but it had a wide-range of suppressive activity on the wild-type virus as well as the Alpha, Beta, Delta, Kappa, Omicron BA.1, and BA.2 variants. With the combined use of EV053273 and EV053286, we observed similar inhibitory effects on viral replication as with REGN-COV in vitro. We further assessed their activity in vivo by using a mouse model infected with a recently established viral strain with adopted infectious activity in mice. Independent experiments revealed that the combined use of EV053273 and EV053286 or the single use of each monoclonal antibody efficiently blocked infection in vivo. Together with data showing that these two monoclonal antibodies could neutralize REGN-COV escape variants and the Omicron variant, our findings suggest that the EV053273 and EV053286 monoclonal antibody cocktail is a novel clinically applicable therapeutic candidate for SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.